Aclasta (zoledronic acid 5 mg) has received European Union approval as the first once yearly treatment for women with postmenopausal osteoporosis. The announcement closely follows the recent approval in the US, where the Food and Drug Administration (FDA) approved Aclasta under the brand name Reclast in August 2007. The European Commission decision applies to all 27 member states, Norway and Iceland. [click link for full article]

More: continued here

This entry was posted on Tuesday, October 9th, 2007 at 7:10 am and is filed under Bones. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.